Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Research & Development (2016 - 2025)

Historic Research & Development for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to $15.9 million.

  • KalVista Pharmaceuticals' Research & Development fell 3706.04% to $15.9 million in Q2 2025 from the same period last year, while for Apr 2025 it was $90.3 million, marking a year-over-year increase of 3181.09%. This contributed to the annual value of $71.7 million for FY2025, which is 1677.9% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Research & Development of $15.9 million as of Q2 2025, which was down 3706.04% from $26.6 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Research & Development ranged from a high of $26.6 million in Q3 2024 and a low of $15.9 million during Q2 2025